Publication:
EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Thumbnail Image

Files

PIIS0923753420428637.pdf (103.52 KB)

relationships.isOrgUnitOf

Program

relationships.isAuthorOf

Author

Sezer, A.

Kilickap, S.

Gumus, M.

Bondarenko, I.

ÖZGÜROĞLU, Mustafa

Gogishvili, M.

TÜRK, HACI MEHMET

Cicin, I.

Bentsion, D.

Gladkov, O.

Advisor

Date

2020-09-01T00:00:00Z

Language

Type

Conference Paper

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Description

Source

Keywords

Keywords

Sezer A., Kilickap S., Gumus M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., TÜRK H. M. , Cicin I., Bentsion D., Gladkov O., et al., -EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%-, ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31

Citation

URI

http://hdl.handle.net/20.500.12645/27357

Collections

Yayınlar - Eserler

Endorsement

Review

Supplemented By

Referenced By

3

Views

112

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Item type:Goal, Access status: Metadata only ,